SYDNEY, Dec. 10, 2015 /PRNewswire/ -- Benitec Biopharma
Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) a clinical-stage
biotechnology company developing innovative therapeutics based on
its gene silencing technology, DNA-directed RNA interference
(ddRNAi), today announced that the Company will host a conference
call and live audio webcast on Tuesday,
December 15, 2015, at 4:30 pm
ET/ Wednesday, December 16, at
8.30am AEST, to provide an
operational update. Interim CEO, Greg
West will provide an overview of Benitec's current and
planned corporate and clinical activities.
Conference Call and Webcast Information:
Interested participants and investors may access the conference
call and Q&A by dialing either +1 877 870-4263 (U.S.) or +1
412-317-0790 (International), and request to join the Benitec
Biopharma conference call. Investors can also access a live, audio
webcast link at https://www.webcaster4.com/Webcast/Page/1346/12373
to hear the update. It is recommended investors dial in or log on
five minutes before the the call commences.
An archive of the webcast will remain available on Benitec's
website for 90 days beginning at approximately 5:30 pm, ET on December
15, 2015.
For further information regarding Benitec and its activities,
please contact the persons below, or visit the Benitec website at
www.benitec.com
Company
|
Investor
relations
|
United
States
|
|
|
|
Carl
Stubbings Chief Business
Officer Tel: +61 (2) 9555
6986 Email:
cstubbings@benitec.com
|
Annabel
Murphy
Head of Investor
Relations &
Corporate Communications
Tel: +61 (2) 9555
6986
Email:
amurphy@benitec.com
|
PCG Advisory
Group
Adam
Holdsworth
Managing Director of
Investor Relations
Tel: + 1
646-862-4607
Email:
adamh@pcgadvisory.com
Sean Leous
Managing Director of
Public Relations
Tel: +1
646-863-8998
Email:
sleous@pcgadvisory.com
|
About Benitec Biopharma Limited:
Benitec
Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a
clinical-stage biotechnology company developing innovative
therapeutics based on its patented gene-silencing technology called
ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and
licensees around the world, the company is developing ddRNAi-based
therapeutics for chronic and life-threatening human conditions
including hepatitis C and B, wet age-related macular degeneration
and OPMD. Benitec has also licensed ddRNAi to other
biopharmaceutical companies for applications including HIV/AIDS,
Huntington's Disease, chronic neuropathic pain and retinitis
pigmentosa.
Safe Harbor Statement:
This press release contains "forward-looking statements" within the
meaning of section 27A of the US Securities Act of 1933 and section
21E of the US Securities Exchange Act of 1934. Benitec has tried to
identify such forward-looking statements by use of such words as
"expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions,
but these words are not the exclusive means of identifying such
statements. Such statements include, but are not limited to, any
statements relating to Benitec's pipeline of ddRNAi-based
therapeutics, including the initiation, progress and outcomes of
clinical trials and any other statements that are not historical
facts. Such forward-looking statements involve risks and
uncertainties, including, but not limited to, risks and
uncertainties relating to the difficulties or delays in our plans
to develop and potentially commercialize our product candidates,
the timing of the initiation and completion of preclinical and
clinical trials, the timing of patient enrolment and dosing in
clinical trials, the timing of expected regulatory filings, the
clinical utility and potential attributes and benefits of ddRNAi
and our product candidates, potential future out-licenses and
collaborations, our intellectual property position and duration of
our patent portfolio, the ability to procure additional sources of
financing and other risks detailed from time to time in filings
that Benitec makes with US Securities and Exchange Commission,
including our most recent annual report on Form 20-F and our
reports on Form 6-K. Such statements are based on management's
current expectations, but actual results may differ materially due
to various factors, including those risks and uncertainties
mentioned or referred to in this press release. Accordingly, you
should not rely on those forward-looking statements as a prediction
of actual future results.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/benitec-biopharma-to-host-corporate-update-conference-call-300191657.html
SOURCE Benitec Biopharma Limited